UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549  FORM 10-QSB   [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For quarterly period ended June 30, 2007  [   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Commission File No.  000-30991  SKINOVATION PHARMACEUTICAL INCORPORATED (Exact name of small business issuer as specified in its charter)  Nevada
(State of incorporation)87-0458170
(I.R.S.  Employer Identification No.)  2157 S. Lincoln Street, Salt Lake City, Utah   84106 (Address of principal executive offices)  (801) 323-2395 (Issuers telephone number)  Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  [X]    No [   ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  [X]    No [   ]  As of August 1, 2007, Skinovation Pharmaceutical Incorporated had a total of 708,000 shares of common stock issued and outstanding.  Transitional small business disclosure format:  Yes [  ]  No [X]   TABLE OF CONTENTS  PART I: FINANCIAL INFORMATION  Item 1.  Financial Statements 2  Item 2. Managements Discussion and Analysis or Plan of Operation 7  Item 3. Controls and Procedures 7  PART II: OTHER INFORMATION  Item 6.  Exhibits 8  Signatures 8     PART I:   FINANCIAL INFORMATION   ITEM 1. FINANCIAL STATEMENTS  The financial information set forth below with respect to our statements of operations for the three and six month periods ended June 30, 2007 and 2006 is unaudited.  This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data.  The results of operations for the six month period ended June 30, 2007 are not necessarily indicative of results to be expected for any subsequent period.         Skinovation Pharmaceutical Incorporated  (A Development Stage Company)  Financial Statements  June 30, 2007             2     Skinovation Pharmaceuticals, Inc.(A Development Stage Company)Balance SheetsASSETSJune 30,December 31,20072006(Unaudited)CURRENT ASSETSCash$          9,669$            346TOTAL ASSETS$          9,669$            346LIABILITIES AND STOCKHOLDERS' DEFICITCURRENT LIABILITIESAccounts Payable - Related party$        38,726$        38,726Accounts Payable26,80014,600Total Current Liabilities65,52653,326Total Liabilities65,52653,326STOCKHOLDERS' DEFICITCommon Stock, $.001 par value; 50,000,000 sharesauthorized; 708,000 shares issued and outstanding708708Additional Paid in Capital25,14825,148Deficit Accumulated During the Development Stage(81,713)(78,836)Total Stockholders' Deficit(55,857)(52,980)TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)$          9,669$            346         3     Skinovation Pharmaceutical, Inc.(A Development Stage Company)Statements of Operations(Unaudited)For the three monthsFor the three monthsFor the six monthsFor the six monthsFrom Inception onended June 30,ended June 30,ended June 30,ended  June 30,January 15, 19882007200620072006to June 30, 2007REVENUES$                       -$                       -$                      -$                       -$            27,937EXPENSESGeneral & Administrative2,8774,3732,8774,621146,725TOTAL EXPENSES2,8774,3732,8774,621146,725NET LOSS FROMCONTINUING OPERATIONS(2,877)(4,373)(2,877)(4,621)(118,788)OTHER INCOME (EXPENSE)Gain on disposal of operations----37,075NET LOSS BEFORE TAXES(2,877)(4,373)(2,877)(4,621)(81,713)TAXES-----NET LOSS$             (2,877)$             (4,373)$           (2,877)$            (4,621)$          (81,713)NET LOSS PER SHARE$                0.00$               (0.01)$              0.00$              (0.01)$              (0.19)WEIGHTED AVERAGESHARES OUTSTANDING708,000708,000708,000708,000421,996               4     Skinovation Pharmaceuticals, Inc.(A Development Stage Company)Statements of Cash Flows(Unaudited)From Inception onFor the six months endedJanuary 15, 1988June 30,Through20072006June 30, 2007Cash Flows from Operating ActivitiesNet Loss$      (2,877)$      (4,621)$           (81,713)Adjustments to reconcile net (loss) to cash provided(used) by operating activities:Shares issued for services--10,433Shares issued for debt payment--1,424Loss on disposal of PP&E5,263Changes in assets and liabilities:Increase in accounts payable and accrued expenses12,2009,00065,526Net Cash Provided (Used) by Operating Activities9,3234,379933Cash Flows from Investing ActivitiesCash paid for PP&E--(5,264)Net Cash Provided (Used) by Investing Activities--(5,264)Cash Flows from Financing ActivitiesCash paid for offering costs--(7,000)Common stock issued for cash--21,000Net Cash Provided (Used) by Financing Activities--14,000Increase (Decrease) in Cash9,3234,3799,669Cash and Cash Equivalents at Beginning of Period346771-Cash and Cash Equivalents at End of Period$       9,669$        5,150$               9,669Supplemental Cash Flow Information:Stock issued for debt payment$               -$               -$               1,424Stock issued for services$               -$               -$             10,433Cash Paid For:Interest$               -$               -$                       -Income Taxes$               -$               -$                       -     5    Skinovation Pharmaceutical Incorporated Notes to the Financial Statements June 30, 2007   GENERAL  Skinovation Pharmaceutical Incorporated (the Company) has elected to omit substantially all footnotes to the financial statements for the six months ended June 30, 2007 since there have been no material changes (other than indicated in other footnotes) to the information previously reported by the Company in their Annual Report filed on the Form 10-KSB for the twelve months ended December 31, 2006.  UNAUDITED INFORMATION  The information furnished herein was taken from the books and records of the Company without audit.  However, such information reflects all adjustments which are, in the opinion of management, necessary to properly reflect the results of the interim period presented.  The information presented is not necessarily indicative of the results from operations expected for the full fiscal year.   6    In this report references to Skinovation, we, us, and our refer to Skinovation Pharmaceutical Incorporated.  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS  The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions.  This report contains these types of statements.  Words such as may, will, expect, believe, anticipate, estimate, project, or continue or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements.  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  ITEM 2.  MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION  During the next twelve months our management intends to actively seek an operating company to acquire or merge with which may provide operating revenue.  Based on current economic and regulatory conditions, management believes that it is possible, if not probable, for a company like ours, without many assets or liabilities, to negotiate a merger or acquisition with a viable private company.  The opportunity arises principally because of the high legal and accounting fees and the length of time associated with the process of going public.  However, should a merger or acquisition prove unsuccessful, it is possible that we may decide not to pursue further acquisition activities and management may abandon its activities and our shares would become worthless.  As of the date of this filing, we have not identified any assets or business opportunities for acquisition.  Potential investors must recognize that because we have limited capital available for investigation of business opportunities and managements limited experience in business analysis, we may not discover or adequately evaluate adverse facts about any business opportunity to be acquired.  All risks inherent in new and inexperienced enterprises are inherent in our plan.  It is emphasized that our management may effect transactions having a potentially adverse impact upon our shareholders pursuant to the authority and discretion of our management to complete acquisitions without submitting any proposal to the stockholders for their consideration.  As of June 30, 2007 we had $9,669 cash on hand, with total current liabilities of $65,526 and have not recorded revenues for the past two years.  Our independent registered accounting firm has expressed doubt that we can continue as a going concern unless we obtain financing.  The majority of our operating expenses are related to our reporting obligations under the Exchange Act.  These expenses include legal, accounting and professional services and costs required to prepare and file our reports with the SEC.  We are unable to pay cash for these services and historically we have relied on loans or related parties to pay for costs on our behalf.  We may repay our debt with cash, if available, or may convert the debt into common stock.  If we obtain a business opportunity, then it may be necessary to raise additional capital.  We likely will sell our common stock to raise this additional capital.  We expect to issue such stock pursuant to exemptions provided by federal and state securities laws.  The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions.  We do not currently intend to make a public offering of our stock.  We also note that if we issue more shares of our common stock, then our shareholders may experience dilution in the value per share of their common stock.  ITEM 3.  CONTROLS AND PROCEDURES  We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC.  This information is accumulated and communicated to our executive officers to allow timely decisions regarding required disclosure.  Our President, who acts in the capacity of principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of  7    the end of the period covered by this report.  Based on that evaluation, he concluded that our disclosure controls and procedures were effective.  Also, he determined that there were no changes made in our internal controls over financial reporting during the second quarter of 2007 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.  PART II:  OTHER INFORMATION  ITEM 6.  EXHIBITS  Part I Exhibits 31.1 Principal Executive Officer Certification 31.2 Principal Financial Officer Certification 32.1 Section 1350 Certification  Part II Exhibits 3.1 Articles of Incorporation as amended  (Incorporated by reference to exhibit 3.1 of the Form 10-KSB, filed March 29, 2002) 3.2 Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the Form-SB, filed July 11, 2000)    SIGNATURES  In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  Date: August 8, 2007SKINOVATION PHARMACEUTICAL INCORPORATED



By: /s/ John W. Peters
John W. Peters
President, Principal Executive Officer,
Principal Financial Officer, and Director   8